F-Star, previously backed by Merck Serono Ventures, signed a deal with the corporate venturing unit’s Germany-based parent, Merck Serono, yesterday to collaborate on the discovery and development of treatments for inflammatory disease. The tie-up could be worth more than €492m ($691.4m) to F-Star if it meets certain milestones, and it would also be eligible for tiered royalties, a statement said.
Susan Herbert, head of portfolio development at Merck Serono, said: "We are very pleased to see our investment in…
